Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy.

J Infect Dis. 1999 Mar;179(3):697-700. Unique Identifier : AIDSLINE MED/99137809
Karavellas MP; Plummer DJ; Macdonald JC; Torriani FJ; Shufelt CL; Azen SP; Freeman WR; Department of Ophthalmology, Shiley Eye Center, University of; California, San Diego, La Jolla, CA 92093-0946, USA.; mkaravellas@netscape.net

Abstract: This study was conducted to determine the likelihood of the development of a new ocular inflammatory syndrome (immune recovery vitritis, IRV), which causes vision loss in AIDS patients with cytomegalovirus (CMV) retinitis, who respond to highly active antiretroviral therapy (HAART). We followed 30 HAART-responders with CD4 cell counts of >/=60 cells/mm3. Patients were diagnosed with IRV if they developed symptomatic vitritis of >/=1+ severity associated with inactive CMV retinitis. Symptomatic IRV developed in 19 (63%) of 30 patients and in 26 (59%) of 44 eyes over a median follow-up from HAART response of 13.5 months. The annual incidence of IRV was 83/100 person-years. Excluding patients with previous cidofovir therapy did not significantly alter the time course of IRV (P=.79). These data suggest that IRV develops in a significant number of HAART-responders with CMV retinitis and is unrelated to previous cidofovir therapy.

Keywords: JOURNAL ARTICLE Antiviral Agents/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/COMPLICATIONS/*DRUG THERAPY/ VIROLOGY California/EPIDEMIOLOGY Cohort Studies Cytomegalovirus Retinitis/*COMPLICATIONS/*DRUG THERAPY Cytosine/ANALOGS & DERIVATIVES/THERAPEUTIC USE Eye Diseases/*EPIDEMIOLOGY/ETIOLOGY Follow-Up Studies Human Incidence Inflammation Organophosphorus Compounds/THERAPEUTIC USE Prospective Studies Retrospective Studies Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Syndrome Time Factors Visual Acuity Vitreous Body/IMMUNOLOGY/*PATHOLOGY
990630
A9960908

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .